Actively Recruiting
Comparison of Response Between Combination of Transarterial Chemoembolization and Lenvatinib Therapy Versus Lenvatinib Monotherapy in Patients With Unresectable Hepatocellular Carcinoma
Led by Bangladesh Medical University · Updated on 2026-02-13
40
Participants Needed
1
Research Sites
77 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this interventional study is to compare treatment response between transarterial chemoembolization (TACE) combined with lenvatinib and lenvatinib monotherapy in patients with unresectable hepatocellular carcinoma. The study aims to determine whether the addition of TACE to lenvatinib results in improved tumor response compared with lenvatinib alone in a real-world clinical setting.
CONDITIONS
Official Title
Comparison of Response Between Combination of Transarterial Chemoembolization and Lenvatinib Therapy Versus Lenvatinib Monotherapy in Patients With Unresectable Hepatocellular Carcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 to 75 years
- Confirmed hepatocellular carcinoma by dynamic CT scan, MRI, or histopathology
- Cancer stage early (A), intermediate (B, subgroup B), or advanced (C) according to BCLC 2022 criteria
- No prior treatment for hepatocellular carcinoma
- At least one measurable tumor lesion based on mRECIST criteria
- ECOG performance status of 0 to 2
You will not qualify if you...
- Diffuse bi-lobar or multinodular hepatocellular carcinoma with 10 or more nodules and 50% or more liver involvement
- Hepatocellular carcinoma with thrombosis in the main trunk of the portal vein
- Child Turcotte Pugh Score of 10 (class C) or higher
- ALBI grade 3 liver function
- Uncontrolled hypertension, recent myocardial infarction, or other thromboembolic events
- Known allergy or intolerance to lenvatinib
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Department of Hepatology, Bangladesh Medical University
Dhaka, Bangladesh, 1000
Actively Recruiting
Research Team
S
Sourav Kumar Chakraborty
CONTACT
M
Md. Ayub Al Mamun, FCPS (Medicine)
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here